Literature DB >> 26303799

Novel insights into the molecular events linking to cell death induced by tetracycline in the amitochondriate protozoan Trichomonas vaginalis.

Kuo-Yang Huang1, Fu-Man Ku2, Wei-Hung Cheng3, Chi-Ching Lee4, Po-Jung Huang4, Lichieh Julie Chu5, Chih-Chieh Cheng6, Yi-Kai Fang3, Hsueh-Hsia Wu7, Petrus Tang8.   

Abstract

Trichomonas vaginalis colonizes the human urogenital tract and causes trichomoniasis, the most common nonviral sexually transmitted disease. Currently, 5-nitroimidazoles are the only recommended drugs for treating trichomoniasis. However, increased resistance of the parasite to 5-nitroimidazoles has emerged as a highly problematic public health issue. Hence, it is essential to identify alternative chemotherapeutic agents against refractory trichomoniasis. Tetracycline (TET) is a broad-spectrum antibiotic with activity against several protozoan parasites, but the mode of action of TET in parasites remains poorly understood. The in vitro effect of TET on the growth of T. vaginalis was examined, and the mode of cell death was verified by various apoptosis-related assays. Next-generation sequencing-based RNA sequencing (RNA-seq) was employed to elucidate the transcriptome of T. vaginalis in response to TET. We show that TET has a cytotoxic effect on both metronidazole (MTZ)-sensitive and -resistant T. vaginalis isolates, inducing some features resembling apoptosis. RNA-seq data reveal that TET significantly alters the transcriptome via activation of specific pathways, such as aminoacyl-tRNA synthetases and carbohydrate metabolism. Functional analyses demonstrate that TET disrupts the hydrogenosomal membrane potential and antioxidant system, which concomitantly elicits a metabolic shift toward glycolysis, suggesting that the hydrogenosomal function is impaired and triggers cell death. Collectively, we provide in vitro evidence that TET is a potential alternative therapeutic choice for treating MTZ-resistant T. vaginalis. The in-depth transcriptomic signatures in T. vaginalis upon TET treatment presented here will shed light on the signaling pathways linking to cell death in amitochondriate organisms.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26303799      PMCID: PMC4604415          DOI: 10.1128/AAC.01779-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  55 in total

1.  In vitro metronidazole and tinidazole activities against metronidazole-resistant strains of Trichomonas vaginalis.

Authors:  Andrea L Crowell; Kolby A Sanders-Lewis; W Evan Secor
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

2.  Prevalence of metronidazole-resistant Trichomonas vaginalis in a gynecology clinic.

Authors:  G Schmid; E Narcisi; D Mosure; W E Secor; J Higgins; H Moreno
Journal:  J Reprod Med       Date:  2001-06       Impact factor: 0.142

Review 3.  Trichomoniasis.

Authors:  Jane R Schwebke; Donald Burgess
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

4.  Anaerobic pyruvate metabolism of Tritrichomonas foetus and Trichomonas vaginalis hydrogenosomes.

Authors:  A Steinbüchel; M Müller
Journal:  Mol Biochem Parasitol       Date:  1986-07       Impact factor: 1.759

5.  Craniofacial and axial skeletal defects induced by the fungicide triadimefon in the mouse.

Authors:  Elena Menegola; Maria Luisa Broccia; Francesca Di Renzo; Valentina Massa; Erminio Giavini
Journal:  Birth Defects Res B Dev Reprod Toxicol       Date:  2005-04

6.  Midline facial defect as a teratogenic effect of metronidazole.

Authors:  J M Cantú; D García-Cruz
Journal:  Birth Defects Orig Artic Ser       Date:  1982

7.  Targeted gene replacement of a ferredoxin gene in Trichomonas vaginalis does not lead to metronidazole resistance.

Authors:  Kirkwood M Land; Maria G Delgadillo-Correa; Jan Tachezy; Stepanka Vanacova; Christine L Hsieh; Robert Sutak; Patricia J Johnson
Journal:  Mol Microbiol       Date:  2004-01       Impact factor: 3.501

8.  The amitochondriate eukaryote Trichomonas vaginalis contains a divergent thioredoxin-linked peroxiredoxin antioxidant system.

Authors:  Graham H Coombs; Gareth D Westrop; Pavel Suchan; Gabriela Puzova; Robert P Hirt; T Martin Embley; Jeremy C Mottram; Sylke Müller
Journal:  J Biol Chem       Date:  2003-11-20       Impact factor: 5.157

9.  GiardiaDB and TrichDB: integrated genomic resources for the eukaryotic protist pathogens Giardia lamblia and Trichomonas vaginalis.

Authors:  Cristina Aurrecoechea; John Brestelli; Brian P Brunk; Jane M Carlton; Jennifer Dommer; Steve Fischer; Bindu Gajria; Xin Gao; Alan Gingle; Greg Grant; Omar S Harb; Mark Heiges; Frank Innamorato; John Iodice; Jessica C Kissinger; Eileen Kraemer; Wei Li; John A Miller; Hilary G Morrison; Vishal Nayak; Cary Pennington; Deborah F Pinney; David S Roos; Chris Ross; Christian J Stoeckert; Steven Sullivan; Charles Treatman; Haiming Wang
Journal:  Nucleic Acids Res       Date:  2008-09-29       Impact factor: 16.971

Review 10.  Mitochondrial defects in cancer.

Authors:  Jennifer S Carew; Peng Huang
Journal:  Mol Cancer       Date:  2002-12-09       Impact factor: 27.401

View more
  3 in total

Review 1.  Trichomoniasis - are we giving the deserved attention to the most common non-viral sexually transmitted disease worldwide?

Authors:  Camila Braz Menezes; Amanda Piccoli Frasson; Tiana Tasca
Journal:  Microb Cell       Date:  2016-06-27

Review 2.  Selective toxicity of antibacterial agents-still a valid concept or do we miss chances and ignore risks?

Authors:  Axel Dalhoff
Journal:  Infection       Date:  2020-12-23       Impact factor: 7.455

Review 3.  Recent advances in the molecular biology of the protist parasite Trichomonas vaginalis.

Authors:  David Leitsch
Journal:  Fac Rev       Date:  2021-03-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.